

Title (en)  
TREATMENT OF AUTOIMMUNE DISEASE USING TOLERIZATION IN COMBINATION WITH METHOTREXATE

Title (de)  
BEHANDLUNG VON AUTOIMMUNERKRANKUNGEN ANHAND EINER TOLERANZERHOEHUNG BEWIRKT DURCH DIE KOMBINATION MIT METHOTREXAT

Title (fr)  
TRAITEMENT DES MALADIES AUTO-IMMUNES A L'AIDE D'UNE TOLERANCE INDUITE EN COMBINAISON AVEC DU METHOTREXATE

Publication  
**EP 0994717 A4 20000726 (EN)**

Application  
**EP 98908452 A 19980126**

Priority

- US 9801648 W 19980126
- US 3672297 P 19970124

Abstract (en)  
[origin: WO9832451A1] A combination of a mucosally administrable bystander antigen and an orally, enterally, or parenterally administrable methotrexate is employed to make a pharmaceutical formulation and to treat or prevent autoimmune disease. The amounts of bystander antigen and methotrexate are effective in combination to suppress autoimmune response associated with the autoimmune disease.

IPC 1-7  
**A61K 31/505**; A61K 39/00; A61P 37/00

IPC 8 full level  
**A61K 31/519** (2006.01); **A61K 38/00** (2006.01); **A61K 38/17** (2006.01); **A61K 38/26** (2006.01); **A61K 38/28** (2006.01); **C07D 475/08** (2006.01); **A61K 38/39** (2006.01); **A61K 38/51** (2006.01); **A61K 39/00** (2006.01); **A61P 3/10** (2006.01); **A61P 19/04** (2006.01); **A61P 27/02** (2006.01); **A61P 29/00** (2006.01); **A61P 37/06** (2006.01); **B41J 2/21** (2006.01); **H04N 1/60** (2006.01)

CPC (source: EP KR)  
**A61K 31/519** (2013.01 - EP); **A61K 39/00** (2013.01 - KR); **A61K 39/0008** (2013.01 - EP); **A61P 3/10** (2018.01 - EP); **A61P 19/04** (2018.01 - EP); **A61P 27/02** (2018.01 - EP); **A61P 29/00** (2018.01 - EP); **A61P 37/00** (2018.01 - EP); **A61P 37/06** (2018.01 - EP); **B41J 2/2107** (2013.01 - EP); **A61K 2039/542** (2013.01 - EP); **G06K 2215/0094** (2013.01 - EP); **G06K 2215/0097** (2013.01 - EP)

Citation (search report)

- [Y] WO 9640235 A1 19961219 - NEXSTAR PHARMACEUTICALS INC [US]
- [Y] WO 9641644 A1 19961227 - NIPPON MEAT PACKERS [JP], et al
- [Y] EP 0666080 A1 19950809 - BRIGHAM & WOMENS HOSPITAL [US]
- [Y] WO 9204049 A1 19920319 - UNIV UTRECHT [NL], et al
- [DY] WO 9316724 A1 19930902 - AUTOIMMUNE INC [US]
- [PX] AL-SABBAGH, A.M., ET AL.: "Combination of oral antigens with oral methotrexate enhances suppression of autoimmune disease", JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, vol. 99, no. 1(PART 2), Abs. 99, January 1997 (1997-01-01), pages s24, XP000909440
- See also references of WO 9832451A1

Designated contracting state (EPC)  
AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

DOCDB simple family (publication)  
**WO 9832451 A1 19980730**; AU 6648898 A 19980818; BR 9807112 A 20010918; CA 2278152 A1 19980730; EP 0994717 A1 20000426; EP 0994717 A4 20000726; HU P0001960 A2 20001028; IL 131025 A0 20010128; JP 2001511134 A 20010807; KR 20000070460 A 20001125; NO 993600 D0 19990723; NO 993600 L 19990923

DOCDB simple family (application)  
**US 9801648 W 19980126**; AU 6648898 A 19980126; BR 9807112 A 19980126; CA 2278152 A 19980126; EP 98908452 A 19980126; HU P0001960 A 19980126; IL 13102598 A 19980126; JP 53225298 A 19980126; KR 19997006698 A 19990724; NO 993600 A 19990723